Gleevec Extends Post-Surgery GIST Survival Significantly; Wins Full Adjuvant Approval
This article was originally published in The Pink Sheet Daily
Patients who took Novartis’ Gleevec for three years after surgery to remove gastrointestinal stromal tumors had a 54% reduction in risk of recurrence and a 55% reduction in risk of death compared to patients who took it for only one year.
You may also be interested in...
After a prior rejection, Britain’s NICE has backed Novartis’ Glivec for KIT (CD117)-positive GISTS, even accepting an expanded-treatment duration of three years compared to the original single year.
Notice of violation letter to Novartis from FDA’s Office of Prescription Drug Promotion expresses concern about describing a patient with five-year survival data, a claim that was added to the label the following month.
With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.